PerkinElmer GSP Neonatal Creatine Kinase – MM (CK-MM) kit
PerkinElmer launched the GSP Neonatal Creatine Kinase –MM (CK-MM) kit, a screening kit for Duchenne muscular dystrophy, which is a progressive X-chromosome linked neuromuscular disorder with a worldwide average incidence rate of approximately 1 in 5,000 male live births. The kit is an immunoassay for measuring CK-MM in newborn babies' dried blood spot samples. The company says the assay is the first commercially available in-vitro diagnostic kit for newborn screening of Duchenne muscular dystrophy. Previously the only available alternative for biochemical assessment of CK levels in dried blood spot samples for newborn screening consisted of non-standardized lab developed tests based on CK enzyme activity measurement, according to the company.